Dr. Sven De Vos
Dr. Christos Emmanouilides
Dr. William H. McBride
Dr. Jonathan W. Said
University of Southern California
Jonsson Comprehensive Cancer Center
Grant Amount: $150,000
PHASE ONE sponsored an Indisciplinary Grant to study the use of the Proteasome Inhibitor PS-341 in the treatment of refractory diffuse large B-cell lymphomas in terms of clinical efficacy, mechanisms of resistance and new models of combination therapy. The study was conducted by principal investigator, Sven de Vos, M.D., and co-investigators, Christos Emmanouilides, M.D., William H. McBride, M.D. and Jonathan W. Said, M.D. at the Jonsson Comprehensive Cancer Center.